Bionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications
- A scientific workshop will feature Dr.
Rashmi Kanagal-Shamanna from theUniversity of Texas MD Anderson Cancer Center delivering a presentation on the use of emerging technologies for prognostication and research into myeloid neoplasms - Four scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research, including one poster covering a multi-site study in
Spain on data analysis for OGM for leukemia and lymphoma research, will be presented at the conference
ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease. The ASH conference will be held
Poster presentations and scientific workshop sessions on OGM include:
Poster Number | Title | Authors | Presented |
2177 | Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping Analysis for Cytogenomic Characterization of Hematological Malignancies: A Spanish Multicentric Study | Puiggros A., Mallo M., Salido M., Gómez-García A., Cisneros A., |
Session 803 |
3496 | Combined Structural Variant and Mutation Profiling for Comprehensive Characterization for Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype | Kanagal-Shamanna, R., Yang H., |
Session 803 |
3496 | Combined Structural Variant and Mutation Profiling for Comprehensive Characterization for Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype | Kanagal-Shamanna, R., Yang H., |
Session 803 |
4134 | Sahajpal N., Mondal A., Jillella A., Kota V., Kolhe R. | Session 617 |
|
4148 | Deciphering the Somatic and Germline Structural Variation Landscape in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Optical Mapping | Brandes D., Brozou T., Nebral K., Bergmann A., Haas O., Köhrer S., Stanulla M., Fischer U., Borkhardt A., Wagener R. | Session 618 |
Session | Title | Author/Affiliation | Presented |
Harnessing Emerging Technologies for Accurate Genomic Classification, Prognostication and Therapeutic Discovery in Myeloid Neoplasms | Kanagal-Shamanna R., |
Dr.
More details on the conference can be found here.
About
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.
Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “should,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility for research in areas including myeloid cancer, hematological malignancy, leukemia and blood disorders, and the growth and adoption of OGM. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as the impact of the COVID-19 pandemic and the ongoing
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics